CE Mark approval gives EnteroMedics the ability to market the Maestro System to countries of the European Economic Area.
The following EU countries are included:
The following EFTA countries are included:
Makes sense. We didn't get that amount of volume last week because of Orex.
Yep, I totally agree it has been a downward spiral since the publication was released. If I am wrong it won't be because I didn't do my DD. I am sticking with what I know to be true rather then what I don't know. What I do know is the FDA is most likely going to approve the device. I don't see how they couldn't after approving more harmful pills. I know there's a huge need for something to combat obesity and pills just don't seem to be the answer thus far. I also know that many Doctors have said there is a gap to be filled between pills and bariatric surgery. I guess the only question after that is how well will it be accepted by patients? Looking at the potential population pool I will take my chances. I am contemplating adding more here soon.
Yep I had my suspicion and he confirmed it with a post today. Can't blame the guy for changing his handle though after his reckless posting and stock suggestions.
Hi Oozie "inherent risks" lets hope everyone does there own DD, if not its their own fault. You act like he's some kind of stock consultant who should come with a disclaimer when he post.
"Small caps are really under-performing again and I think that's the main issue here," JC O'Hara, the New York-based chief market technician at FBN Securities Inc, said by phone. "We're seeing the spread between the Russell and the S&P 500 widening out again and that is worrying some people. Traders want to see small caps participate and every time they don't they think, ‘it's still not working.'"
While losses today were biggest in speculative shares, equities declined throughout the U.S. market and around the world after sales of existing homes unexpectedly dropped and China's finance minister damped stimulus hopes.
And why would you care? You "supposedly" do not have a position long nor short so please don't tell me you're here to save the retail investor. It's very clear there's a motive behind your rhetoric. Maybe you're accumulating shares or maybe Ade is on to something and you're working for someone else! By the way you lied. Only 400 shares traded pre-market @ $1.15
Hey Gary good to see you're still here. Are you trading, riding this one out or both? As far as Ade, I think his expectations are unrealistic but I can look beyond that. What we need is a decision soon to hopefully set a floor. Right now there's just to much unknown and nobody seems to want to take on the risk. IF it gets approved hopefully they can start selling the device right away giving us some early sales numbers on the upcoming Qcall. We know there's a backlog of patients waiting, what we don't know is how many. Good luck!
As to why they won't tell us what the backlog looks like in terms of numbers? Why would we not be entitled to know? Just speculating here maybe there's another company involved just waiting for approval.
His sales projection are to high I believe because we are going to rely heavily on self pay patients for now. At least until patients start showing positive results from the device. If we get 25% weight loss then I don't see why providers wouldn't cover the procedure and device. The treat obesity act is something to watch as it could open the door to much better coverage.
I agree they probably aren't getting to much info from the FDA. But they did say they where in discussions with them surrounding the label. Some say this is the norm, but i'm not so sure about that. I would think you would be discussing the label only if you where going to approve the device. For now I'm am more interested in what the backlog looks like. After telling us there's a backlog an analyst asked the question, how many and they wouldn't release the info. Not sure why we are not entitled to know.
Inns: You really believe $15 is possible without reimbursement? I'm not saying we can't get there eventually but in 6mos? If that's the case and there are that many people ready to pull out the credit card there's NO doubt in my mind someone will be jumping all over this company. Medtronic payed $260M some years ago for a company with a similar device that failed as i'm sure you know. I figure a company with an approved device should easily be worth twice that much making it around $500M to $600M So rough math would put us around $7 $8 bucks a share. Anyway hat's my guestimate for now assuming approval of course!.
The Stock market as whole is a casino in today's era. I think everyone here knows or should know this is a gamble and anythings possible including BK. I personally don't see it happening because I believe approval will come shortly. But I could be wrong along with the rest of us longs. But if you really believe what you wrote "the odds are more likely we see fifty cents before we see $2" why would have even taken a position yet? I obviously thought it was a buy with my first purchase at $1.50 or I would have waited to buy at these levels which I have fwiw. Just trying to figure you out that's all. You seem fixated on what ADE is posting. Why? Please don't tell me to save the little guy. I think his expectations are quite high but hey those are his estimates which he backs by numbers. It's almost as if Ade has cost you money somehow. Did you follow a recommendation of his in the past that went bust? I know it sounds like I keep defending the guy but i'm really not.
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), and EnteroMedics Inc. (NASDAQ: ETRM). Have yet to see the full report.
The problem for Medtronic was they bought it out prior to FDA approval. It was never approved. So lets hope ETRM tweaked it enough with their own device to make it a success. If they did which by all accounts it looks like they did then we should be looking good here soon. What happens between now and a decision is meaningless. BUT what you posted should is very valid and should put an estimate of the products value out there for some to ponder! Remember they paid that much for a device still in trials. We already have EU, Australia and most everything in between approved for use. This could be a Goldmine if they play their cards right. Lets hope they do!
Draw your own conclusions:
Mark knudson: Restore Medical Incorporated was acquired by Medtronic, Inc.
Luke Evnin: Metabasis Therapeutics, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Oscient Pharmaceuticals Corp. and Restore Medical, Inc. (acquired by Medtronic, Inc.)
Bobby Griffen: Retired from a 25 year career with Medtronic, Inc.
Mr. Tremmel: Medtronic, Inc he served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007, President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division
I read the article and it's no surprise. The guy seems almost untouchable with SEC turning a blind eye. He also has the benefit of big money backers which in this game is all it takes. I personally think he's toned it down in the last year or so with various stocks he used to hammer on a daily basis, but obviously the damage was already done.